^
Association details:
| Biomarker: | STAG2 mutation |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | Lynparza (olaparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Glioblastoma cells containing mutations in the cohesin component, STAG2, are sensitive to PARP inhibition
Excerpt:
We also used a combination of olaparib and temozolomide (TMZ), an alkylating agent that has previously shown robust synergy with PARP inhibitors and is currently used to treat GBMs. These two drugs together had similar results to those with olaparib and CPT, showing increased sensitivity in STAG2-mutated compared to STAG2 KI lines...
DOI:
10.1158/1535-7163.MCT-13-0749
